3.54%
-8.76%
-16.97%
13.20%
13.15%
316.49%
316.49%
AI Spotlight on ACLX
Company Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases.The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM).It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs.
The company was formerly known as Encarta Therapeutics, Inc.and changed its name to Arcellx, Inc.in January 2016.
Arcellx, Inc.was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Market Data
| Last Price | 69.97 |
| Change Percentage | 3.54% |
| Open | 67.69 |
| Previous Close | 67.58 |
| Market Cap ( Millions) | 3784 |
| Volume | 184057 |
| Year High | 107.37 |
| Year Low | 47.88 |
| M A 50 | 78.75 |
| M A 200 | 69.46 |
Financial Ratios
| FCF Yield | 0.09% |
| Dividend Yield | 0.00% |
| ROE | -8.28% |
| Debt / Equity | 13.53% |
| Net Debt / EBIDTA | 291.44% |
| Price To Book | 7.8 |
| Price Earnings Ratio | -93.16 |
| Price To FCF | 1055.99 |
| Price To sales | 24.28 |
| EV / EBITDA | -111.34 |
News
- Dec -23 - 5 Biotech Breakthrough Stocks to Watch in 2025
- Dec -09 - Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
- Dec -09 - Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
- Nov -13 - Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice
- Nov -08 - Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?
- Nov -07 - Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates
- Nov -07 - Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?
- Sep -10 - Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma
- Aug -08 - Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
- Jul -04 - FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
- Jun -26 - Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market
- May -27 - 7 Biotech Stocks to Put on Your Breakthrough Radar
- May -09 - Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
- May -09 - Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
- May -09 - Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
- May -09 - Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
- Apr -04 - How Arcellx (ACLX) Stock Stands Out in a Strong Industry
- Mar -20 - Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
- Feb -29 - Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference
- Feb -29 - Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Cell Therapies
Expected Growth : 25.4 %
What the company do ?
Arcellx, Inc.'s Cell Therapies involve genetically modified cells that produce antibodies to fight cancer and rare diseases, offering a potential cure.
Why we expect these perspectives ?
Growing demand for cell therapies, increasing cancer prevalence, and advancements in gene editing technologies drive the market growth. Arcellx's innovative approach to producing antibodies through genetically modified cells offers a potential cure, further fueling growth.
Arcellx, Inc. Products
| Product Range | What is it ? |
|---|---|
| Arcellx's CART-ddBCMA | A novel, investigational cell therapy designed to target and eliminate cancer cells that express the B-cell maturation antigen (BCMA), a protein highly expressed on multiple myeloma cells. |
| Arcellx's CART-iX cells | A type of chimeric antigen receptor (CAR) T-cell therapy that targets CD19, a protein expressed on the surface of B cells, for the treatment of B-cell malignancies. |
| Arcellx's CART-BCMA cells | A CAR T-cell therapy that targets BCMA, a protein highly expressed on multiple myeloma cells, for the treatment of multiple myeloma. |
| Arcellx's D-Domain antibodies | A novel class of antibodies that can be used to target specific proteins on the surface of cancer cells, enabling the development of new cancer therapies. |
Arcellx, Inc.'s Porter Forces
Threat Of Substitutes
Arcellx, Inc. operates in the biotechnology industry, which is characterized by high research and development costs. This makes it difficult for new entrants to develop substitutes, reducing the threat of substitutes.
Bargaining Power Of Customers
Arcellx, Inc. primarily sells its products to pharmaceutical companies, which have limited bargaining power due to the specialized nature of the products.
Bargaining Power Of Suppliers
Arcellx, Inc. relies on a few key suppliers for raw materials and equipment. While these suppliers have some bargaining power, Arcellx's strong relationships and diversified supply chain mitigate this risk.
Threat Of New Entrants
The biotechnology industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise. This makes it difficult for new entrants to enter the market.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established players and new entrants vying for market share. Arcellx, Inc. faces intense competition from companies such as Celgene, Gilead Sciences, and Novartis.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 16.75% |
| Debt Cost | 4.24% |
| Equity Weight | 83.25% |
| Equity Cost | 5.08% |
| WACC | 4.94% |
| Leverage | 20.11% |
Arcellx, Inc. : Quality Control
Arcellx, Inc. passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CORT | Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a … |
| NVAX | Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a … |
| RPRX | Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, … |
| ALPN | Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline … |
| EXEL | Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Exelixis
A-Score
1-Year Total Return ->
🥈
Royalty Pharma
A-Score
1-Year Total Return ->
🥉
Corcept Therapeutics
A-Score
1-Year Total Return ->
4
Novavax
A-Score
1-Year Total Return ->
5
Alpine Immune Sciences
A-Score
1-Year Total Return ->
6
